《Journal of Oral and Maxillofacial Surgery》 ›› 2023, Vol. 33 ›› Issue (4): 224-228. doi: 10.12439/kqhm.1005-4979.2023.04.004

• Basic Scientific Study • Previous Articles     Next Articles

Expression of lncRNA CDKN2BAS in oral squamous cell carcinoma and its significance on cell proliferation and invasion

JIANG Shengjun(), CHEN Yan(), JIN Zhongzhi, HUANG Sibo   

  1. Department of Stomatology, Renmin Hospital of Wuhan University,Wuhan 430000, Hubei Province, China
  • Received:2022-05-12 Accepted:2022-09-20 Online:2023-08-28 Published:2023-08-29

LncRNA CDKN2BAS在口腔鳞状细胞癌组织中的表达及对细胞增殖和侵袭的影响

姜胜军(), 陈燕(), 金中直, 黄思博   

  1. 武汉大学人民医院口腔科,湖北 武汉 430000
  • 通讯作者: 陈燕,主治医师. E-mail:245094583@ qq.com
  • 作者简介:
    姜胜军,主治医师. E-mail:
  • 基金资助:
    中央高校基本科研业务费专项资金(2042018kf0145)

Abstract:

Objective: To investigate the expression intensity of lncRNA CDKN2BAS in oral squamous cell carcinoma (OSCC) tissues, and to determine whether the expression level is related to tumor proliferation and invasion.Methods: A total of 96 cases of patients with OSCC treated in our hospital from March 2016 to March 2021 were selected as the research objects. The CAL‐27 cells were cultured and divided into siRNA group, group B and group C, and transfected by using transfection reagent with the small molecule interfering sequence of CDKN2BAS (group siRNA), control sequence (group C) and transfection reagent only (group B), respectively. The real‐time quantitative polymerase chain reaction (RT‐qPCR) was used to detect the expressions of CDKN2BAS in OSCC tissues and cells; the MTT experiment and plate clone formation experiment were usedto detect cell proliferation activity, and the transwell experiment was used to detect cell migration and invasion.Results: Theexpression level of CDKN2BAS in OSCC tissue (2.61±0.21) was significantly higher than that in the control group (1.03±0.11) (P<0.001). The expression level of CDKN2BAS in poorly differentiated tissues was higher than that in medium andhigh differentiation, the expression level of CDKN2BAS in tissues of TNM stage Ⅲ‐Ⅳ was higher than that of stage Ⅰ‐Ⅱ, the expression level of CDKN2BAS in tissues with lymph node metastasis was higher than that in tissues without lymph node metastasis, and the expression level of CDKN2BAS in tissues with vascular involvement was higher than that without vascular recidivism, the differences were statistically significant (P<0.05). The expression level of CDKN2BAS of the cells in the siRNA group was (0.18±0.04), which was significantly lower than those in the group C (1.02±0.08) and group B (1.03±0.10) (P<0.001). The cell absorbance values in the siRNA group at 24, 48, 72 and 96 h were lower than those in the group C and group B (P<0.05). The number of cell clone, migration and invasion in siRNA group were lower than those in the group C and group B (P<0.001).Conclusion: This result suggests that the expression level of CDKN2BAS in OSCC tissues is increased. Silencing the expression of CDKN2BAS in CAL‐27 cells can reduce cell proliferation activity and the number of cell migration and invasion can be decreased.

Key words: oral squamous cell carcinoma, LncRNA CDKN2BAS, clinical indicators, cell biological characteristics

摘要:

目的: 探讨长链非编码RNA(long non‐coding RNA, lncRNA) CDKN2BAS在口腔鳞状细胞癌(oral squamous cell carcinoma, OSCC)组织中的表达,以及其对细胞增殖和侵袭的影响。方法: 以2016年3月—2021年3月在我院治疗的96例OSCC患者为研究对象,培养CAL‐27细胞,并将其分成siRNA组、B组和C组,利用转染试剂分别转染CDKN2BAS的小分子干扰序列(siRNA组)、对照序列(C组)及仅加入转染试剂(B组)。采用实时定量聚合酶链反应(real‐time quantitative polymerase chain reaction, RT‐qPCR)检测OSCC组织和细胞中CDKN2BAS的表达;采用MTT实验和平板克隆形成实验检测细胞增殖活性;采用transwell实验检测细胞迁移和侵袭能力。结果: 相比于对照组的表达量(1.03±0.11),OSCC组织中CDKN2BAS的表达量(2.61±0.21)明显升高(P<0.001);低分化组织中CDKN2BAS的表达量高于其在中、高分化组织中,TNM分期为Ⅲ~Ⅳ期组织中的CDKN2BAS表达量高于其在Ⅰ~Ⅱ期中,淋巴结转移组织中的CDKN2BAS表达量高于其在未发生淋巴结转移的组织中,脉管累犯组织中CDKN2BAS的表达量高于其在未发生脉管累犯的组织中,差异均有统计学意义(P<0.05);相比于C组(1.02±0.08)和B组(1.03±0.10),siRNA组细胞中CDKN2BAS的表达量(0.18±0.04)明显降低(P<0.001);培养24、48、72、96 h时,siRNA组细胞吸光度值均低于B组和C组(P<0.05),siRNA组细胞克隆数、迁移数和侵袭数均低于B组和C组(P<0.001)。结论: OSCC组织中CDKN2BAS表达量高,沉默CAL‐27细胞中CDKN2BAS基因表达可降低细胞增殖活性,减少细胞迁移和侵袭的数量。

关键词: 口腔鳞状细胞癌, LncRNA CDKN2BAS, 临床指标, 细胞生物学特性

CLC Number: